ResearchMoz

Pharmaceutical Industry in China Q3 2013 - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

Kelly Scientific Publications
Published Date » 2013-11-01
No. Of Pages » 145

This report tackles not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities. 

The Chinese Pharmaceutical market is currently the third greatest pharma market globally, after the US and Japan, and in 2011 was worth $x. It is forecast to increase dramatically to $x by 2015 and increase its dominance as a leading player in Asia. As the current third market leader it is predicted that the Chinese pharma market will be the main competitor of the US by 2020. 

This report describes the current therapeutics that are propelling the biopharmaceutical market in China. It examines the current economic climate and how China compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, diabetes and vaccines are elucidated and analysed. 

This study reveals market figures of the overall Chinese pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in China. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. 

In summary, the Chinese biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment. 

Pharmaceutical Industry China Q3 2013 – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 196 tables & figures within 145 pages. The Chinese biopharmaceutical market is presented as follows:

  • By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
  • By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

  • Company financials, sales & revenue figures – historical to Q2•2013
  • China GDP, economic growth, export (bulk drug, formulations) figures
  • Indian health expenditure as a function of GDP
  • Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
  • Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
  • Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Top Five Contract Pharmaceutical Export Markets of China
  • Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
  • Multinational penetration into the Chinese Pharma Market
  • Comprehensive product portfolios, R&D activity and pipeline therapeutics 
  • M&A activity and future strategies of top Chinese pharmacos
  • Economic indicators, trade policy, merchandise and commercial trade statistics
  • Gross Domestic Product of China, historic and projection analysis
  • Chinese economic outlook in comparison to advanced economies 
  • Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth 
  • Prescription drug sales distribution channels in China
  • Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

  • Amoytop Biotech
  • Active Pharmaceutical Products
  • Beijing Continent Pharmaceuticals
  • FusoGen Pharmaceuticals
  • Shanghai Huaguan Biochip
  • SiBiono GeneTech
  • Abbott
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson Medical
  • Merck
  • Novartis
  • Pfizer
  • Roche

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed.  The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed. 

What you will gain:

  • An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
  • Current market facts, figures and product lines of key players in the industry
  • An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
  • Knowledge of how the Chinese pharma market will integrate into the global healthcare market 
  • Information on key regulatory and government policies 
  • Data on levels of private and publically funded biopharma studies in China
  • Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:

  • Lack of regulatory policy and legislation 
  • Reimbursement schemes and payers concerns
  • Funding and government sponsorship issues
  • International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:

  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity
TABLE OF CONTENT

1.0 Summary   8
1.1 Objectives of Report  8
1.2 Scope of Study   9
1.3 Data Sources and Methodology 10
1.4 Key Findings and Observations 10
1.5 Executive Summary  11

2.0 Chronic Disease Prevalence Statistics 14

3.0 Business Environment  16
3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 16
3.2 Gross Domestic Product of China, Historic and Projection Analysis   18
3.3 Annual Health Expenditure in China, Historic and Projected Analysis   19
3.4 Global and Chinese Economic Outlook 2010-2013 20
3.5 Chinese Economic Outlook in Comparison to Emerging Markets and Developing Countries 21
3.6 Chinese Economic Outlook in Comparison to Advanced Economies (US, Europe) 23

4.0 Chinese Pharmaceutical Market 28
4.1 Market Overview  28
4.2 Main Players in China’s Pharmaceutical Industry 31
4.3 Anti-Allergy Drug Market 31
4.4 Asthma Drug Market  32
4.5 Benign Prostate Hyperplasia Drug Market 32
4.6 Anti-Depressant Drug market 33
4.7 Dermatitis  Drug Market 35
4.8 Diabetes Drug Market  36
4.9 Hypertension Drug Market 37
4.10 Dyslipidaemia Drug Market 38
4.11 Senile Dementia Drug Market 39
4.12 Cancer Drug Market  40
4.13 Rheumatoid Arthritis Drug Market 40
4.14 Ophthalmological Drug Market 41
4.15 Liver Disease Drug Market 43
4.16 Antibiotic Drug Market  44

5.0 Government and Regulation Environment 45
5.1 12th Five Year Plan  45
5.2 Intellectual Property for Pharmaceuticals in China 47
5.3 State Food and Drug Administration (SFDA) 52
5.4 Pharmaceutical Distribution Process in China 55

6.0 China – Third Largest Pharma Market 2012 58
6.1 China – At the Forefront of Emerging Markets 58
6.2 Generic Medication Market and China 58
6.3 Novel Product Drug Development 60
6.4 Drug Development Cost and Outsourcing 62
6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals   63
6.6 China’s Pharmaceutical Export Market 63
6.7 Spot Light - China Medical City Taizhou 65

7.0 Global Pharmaceutical Companies Interest in China 67
7.1 Abbott China   67
7.2 AstraZeneca China   75
7.3 Bayer China   83
7.4 Boehringer Ingelheim China  87
7.5 Eli Lilly China 89
7.6 GlaxoSmithKline China  91
7.7 Johnson & Johnson Medical China 96
7.8 Merck China   100
7.9 Novartis China 102
7.10 Novo Nordisk China  105
7.11 Pfizer China   108
7.11.1 Pfizer China R&D Centre 110
7.11.2 Pfizer China Products  110
7.11.3 Pfizer Financials  113
7.11.4 Pfizer Global   114
7.12 Roche China   114
7.13 Sanofi China   120

8.0 Chinese Pharmaceutical Companies 123
8.1 Amoytop Biotech  123
8.2 Active Pharmaceutical Products  125
8.2.1 Research and Development 126
8.2.2 Financial Information  126
8.3 Beijing Continent Pharmaceuticals 126
8.4 FusoGen Pharmaceuticals 127
8.4.1 Financial Information  128
8.5 Shanghai Huaguan Biochip 128
8.5.1 Financial Information  131
8.6 SiBiono GeneTech  131
8.6.1 Financial Information  132
8.7 Sinovac Biotech  132
8.7.1 Financial Information  134
8.7.2 New Products 139
8.7.3 Split Virion Pandemic Influenza Vaccine 139
8.7.4 RabEnd 139
8.7.5 Pipeline Portfolio  139
8.7.6 EV71 virus Vaccine  139
8.7.7 Pneumococcal Conjugate Vaccine 140
8.7.8 Pneumococcal Polysaccharide Vaccine 140
8.7.9 Varicella Vaccine   140
8.7.10 Measles, Mumps and Rubella Vaccines 140
8.7.11 Rotavirus Vaccine  140

9.0 Drivers, Restraints, Challenges and Opportunity Analysis 141
9.1 Key Drivers of the Pharmaceutical Market in China 141
9.2 Key Restraints of the Pharmaceutical Market in China 142
9.3 Challenges of the Pharmaceutical Industry in China 143
9.4 Opportunities Within BioPharma China 145

List of Tables


Table 2.1: Most Prominent Cancer Manifestations in China 15
Table 2.2: Top Fifty Diseases in China Today (non-cancer) 15
Table 2.3: Top Infectious Disease States in China Today 15
Table 3.1: World Trade Organisation Basic Indicators on China 16
Table 3.2: World Trade Organisation Trade Policy of China 16
Table 3.3: World Trade Organisation Merchandise Trade Statistics: China   17
Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China  17
Table 3.5: Summary of International Monetary Fund Members’ Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China  18
Table 3.6: China Statistics  18
Table 4.1: Top Global Pharma Markets 2003-2013 28
Table 4.2: Major Players in China’s Anti-Allergy Drug Market 31
Table 4.3: Major Players in China’s Asthma Drug Market 32
Table 4.4: Major Players in China’s Benign Prostate Hyperplasia (BPH) Drug Market  33
Table 4.5: Major Players in China’s Anti-Depressant Drug Market 34
Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics 35
Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market 35
Table 4.8: Major Players in China’s Dermatitis Drug Market 35
Table 4.9: Major Players in China’s Diabetic Drug Market 37
Table 4.10: Major Players in China’s Hypertension Drug Market 38
Table 4.11: Major Players in China’s Dyslipidaemia Drug Market 38
Table 4.12: Major Players in China’s Senile Dementia Drug Market 39
Table 4.13: Major Players in China’s Cancer Drug Market 40
Table 4.14: Major Players in China’s Rheumatoid Arthritis Drug Market 41
Table 4.15: Major Players in China’s Ophthalmological Drug Market 42
Table 4.16: Major Players in China’s Liver Disease Drug Market 43
Table 4.17: Major Players in China’s Antibiotic Drug Market 44
Table 5.1: Seven Strategic Emerging Industries of China’s 12th Five Year Plan 2011-2015  45
Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012   47
Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China   55
Table 5.4: Prescription Drug Sales Distribution Channels in China 55
Table 6.1: Major Biogeneric Products in China 59
Table 6.2: Imported Therapeutics with Administrative Protection in China   59
Table 6.3: Expired Proprietary Pharmaceuticals in China 60
Table 6.4: Reasons Why Multinational Companies Seek CMO’s in China 62
Table 6.5: Comparison of Clinical Trial Cost between China and the USA   63
Table 6.6: Five Functional Districts of China Medical City 65
Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City   66
Table 7.1: Top Multinational Company Performance, China 67
Table 7.2: Abbott Areas of Expertise 69
Table 7.3: Abbott Key Global Products 71
Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions  71
Table 7.5: Abbott China Anaesthesia Product Profile 71
Table 7.6: Abbott China Cardiovascular Product Profile 72
Table 7.7: Abbott China Vaccine Product Profile 72
Table 7.8: Abbott China Digestion Product Profile 72
Table 7.9: Abbott China HIV Product Profile 72
Table 7.10: Abbott Rheumatology HIV Product Profile 72
Table 7.11 Abbott China Gynaecological Product Profile 72
Table 7.12 Abbott China Urological Product Profile 72
Table 7.13 Abbott China Liver Disease Product Profile 73
Table 7.14 Abbott China Diagnostic Product Profile 73
Table 7.15: Abbott China Molecular Diagnostic Product Profile 73
Table 7.16: Abbott Blood Glucose Meter Product Profile 74
Table 7.17: Abbott Cardiovascular Product Profile 74
Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile   74
Table 7.19: Important Milestones in AstraZeneca China’s History 75
Table 7.20: AstraZeneca China Anaesthetic Range of Products 76
Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products  76
Table 7.22: AstraZeneca China Gastrointestinal Range of Products 76
Table 7.23: AstraZeneca China Infection Range of Products 76
Table 7.24: AstraZeneca China Neurology Range of Products 76
Table 7.25: AstraZeneca China Oncology Range of Products 77
Table 7.26: AstraZeneca China Respiratory Range of Products 77
Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally 2012 79
Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally 2010-2012  79
Table 7.29: Bayer China Important Milestones 84
Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China  85
Table 7.31: Bayer - Leading Therapeutics in China 86
Table 7.32: Bayer Top Selling Consumer Health Products 86
Table 7.33: Boehringer Ingelheim Major Products in China 87
Table 7.34: Main Therapeutic Areas of Interest to Boehringer Ingelheim China   87
Table 7.35: Global Therapeutic Pipeline, Boehringer Ingelheim 88
Table 7.36: Major Global Boehringer Ingelheim Therapeutic Products 88
Table 7.37: GlaxoSmithKline Prescription Portfolio and Indications in China   91
Table 7.38: GlaxoSmithKline Vaccine Portfolio and Indications in China 92
Table 7.39: GlaxoSmithKline Over the Counter Portfolio and Indications in China  92
Table 7.40: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012  94
Table 7.41: GlaxoSmithKline Global Vaccine Sales 2012 95
Table 7.42: Significant Milestones in Johnson and Johnson China History   96
Table 7.43: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area and Percentage Change, 2012  99
Table 7.44: Merck Serono Pharmaceutical Key Therapeutic Areas in China   100
Table 7.45: Merck Serono Fertility and Infertility Therapeutic Portfolio in China   100
Table 7.46: Merck Serono Therapeutic Portfolio in China 101
Table 7.47: Merck Pharmaceutical Hong Kong Therapeutic Portfolio 101
Table 7.48: Range of Diabetic Products from Novo Nordisk China 106
Table 7.49: QUICKFACTs - Pfizer China 109
Table 7.50: Important Milestones – Pfizer China 109
Table 7.51: Pfizer China – Range of Infectious Disease Therapeutics for Chinese Health Care Market 110
Table 7.52: Pfizer China – Range of  Mental Health Products for Chinese Health Care Market  111
Table 7.53: Pfizer China – Range of Genitourinary Products for Chinese Health Care Market  111
Table 7.54: Pfizer China – Range of Endocrine Products for Chinese Health Care Market  111
Table 7.55: Pfizer China – Range of Women’s Health Products for Chinese Health Care Market  111
Table 7.56: Pfizer China – Range of Cardiovascular Disease Products for Chinese Health Care Market 111
Table 7.57: Pfizer China – Range of Oncology Products for Chinese Health Care Market  111
Table 7.58: Pfizer – Key Consumer Healthcare Global Products 112
Table 7.59: Pfizer – Key Speciality Care Global Products 112
Table 7.60: Pfizer – Key Oncology Global Products 112
Table 7.61: Pfizer – Key Global Established Products 112
Table 7.62: Pfizer – Key Innovative Products in Emerging Markets 112
Table 7.63: Pfizer – Key Animal Health Global Products 113
Table 7.64: Pfizer Product Sales with Significant Impact on Revenues 2011:2012 Comparison 113
Table 7.65: Roche Pharmaceuticals Product List in China 115
Table 7.66: Roche Global Sales (CHF Millions) by Therapeutic Area, 2011, 2012 and Percentage Change (CER) 117
Table 7.67: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011, 2012 and Percentage Change (CER) 118
Table 7.68: Seven Growth Platforms of Sanofi China 120
Table 7.69: Key Therapeutic Areas of Sanofi China 120
Table 8.1: Important Milestones in Amoytop Biotech’s Development 123
Table 8.2: Amoytop Biotech – Main Objectives of Research and Development Division  124
Table 8.3: Amoytop Biotech – Panel of Recombinant Protein Therapeutics in Clinical Studies  124
Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China 125
Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech   125
Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech 125
Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals 128
Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals   128
Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio 129
Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile   129
Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio 129
Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio 129
Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio 130
Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech 131
Table 8.15: Gendicine - Potential Oncology Indications for Future Approval   132
Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech 133
Table 8.17: Important Milestones in the History of Sinovac Biotech 133
Table 8.18: Pipeline Portfolio of Sinovac Biotech 133
Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012 135
Table 9.1: Key Drivers of the Pharmaceutical Market in China 141
Table 9.2: Key Restraints of the Pharmaceutical Market in China 142
Table 9.3: Key Challenges of the Pharmaceutical Market in China 143
Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020   144
Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China   145

List of Figures


Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages   14
Figure 3.1: China GDP Figures 2006-2015 19
Figure 3.2: Annual Health Expenditure in China 2006-2015 19
Figure 3.3: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013 20
Figure 3.4: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013 21
Figure 3.5: Global, Emerging Market & Developing Countries & Russia Economic Growth Change 2010-2013 22
Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013 22
Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013 23
Figure 3.8: Global, US and Germany Economic Growth 2010-2013 24
Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017   24
Figure 3.10: Global, France and Italy Economic Growth 2010-2013 25
Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017  25
Figure 3.12: Global, UK and Spain Economic Growth 2010-2013 26
Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013 26
Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017 27
Figure 4.1: The Chinese Healthcare Industry by Sector, 2011 30
Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution 2011-2020 46
Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs 53
Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials 54
Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market  56
Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution Market  56
Figure 6.1: Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth  58
Figure 6.2: Number of Investigational New Drug Applications in China 2003-2010  60
Figure 6.3: Number of New Drug Applications in China 2003-2010 61
Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China  61
Figure 6.5: Percentage of Clinical Trial Drug by Disease State 62
Figure 6.6: China’s Regional Pharmaceutical Processing Trade Export Market Share Percentage   64
Figure 6.7: Contract Amount of China’s Regional Pharmaceutical Processing Trade Export 64
Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China 65
Figure 7.1: Abbott Laboratories Geographic Distribution of Revenue –USA, Established and Emerging Markets   68
Figure 7.2: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015 69
Figure 7.3: Abbott – Business Specialization Strategy 2012: Diversified Medical Products and Research-Based Pharmaceuticals 70
Figure 7.4: Abbott Diversified Medical Product Portfolio 70
Figure 7.5: AstraZeneca Sales Revenue (US$ Millions) in China, 2010-2012   78
Figure 7.6: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Western Europe, Emerging Markets 2012   78
Figure 7.7: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales 2010-2012 80
Figure 7.8: AstraZeneca Gastrointestinal Product (Nexium) Global Sales 2010-2012  80
Figure 7.9: AstraZeneca Infection Product (Synagis) Global Sales 2010-2012   81
Figure 7.10: AstraZeneca Neuroscience Product (Seroquel-IR, -XR) Global Sales 2010-2012 81
Figure 7.11: AstraZeneca Oncology Product (Zoladex) Global Sales 2010-2012   82
Figure 7.12: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 2010-2012 82
Figure 7.13: Boehringer Ingelheim Oncology Compounds in Development   89
Figure 7.14: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 2012 (£ Billions)   93
Figure 7.15: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012  94
Figure 7.16: GlaxoSmithKline Global Vaccine Sales by Therapeutic Area, 2012   95
Figure 7.17: GlaxoSmithKline Global Sales by Geographic Region – USA, Europe, Emerging Markets, Japan, 2012   96
Figure 7.18: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area, 2012  99
Figure 7.19: Novartis International Sales (%) by Geographic Region, 2012   104
Figure 7.20: Novartis International Sales (US$ Millions) by Geographic Region, 2012  104
Figure 7.21: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China 2010-2012 107
Figure 7.22: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China 2010-2012 108
Figure 7.23: Business Sectors – Pfizer China 110
Figure 7.24: Roche Total Global Sales (CHF Millions) 2011, 2012 117
Figure 7.25: Roche Global Sales (CHF Millions) by Therapeutic Area, 2011, 2012  118
Figure 7.26: Roche Pharmaceutical Division Emerging Market Total Sales 2011, 2012  119
Figure 7.27: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011, 2012  119
Figure 7.28: Sanofi Geographic Market Share (%) – Emerging Markets, USA and Western Europe 2012  121
Figure 7.29: Sanofi Geographic Market Share (%) –China, Russia and USA 2012   122
Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression  127
Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service 130
Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012 135
Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012   136
Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012 136
Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012 137
Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012 138
Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011 138

Upcoming Reports:

Membrane Bioreactor (MBR) Market Analysis, Market Size, Share, Trends, Growth And Forecast, 2012 - 2017
By - Transparency Market Research
Membrane bioreactor is a combination of various components which are used for waste water treatment. Membrane bioreactor incorporates two processes to treat water. The  first step is a bioreactor, in which bacteria consumes organic material with the help of dissolved oxygen in the water, and the second step is a membrane module in which relatively pure water separates itself from organic matter and bacteria. These two units run step by step - firstly liquid flows through the bioreactor and then through the membrane separation process. Membrane bioreactors serve the municipal...
Orthopedics Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecast 2009 - 2018
By - Transparency Market Research
Orthopedics is the branch of medical science which deals with healing of bone and muscle related deformities. The global aging population, technological advancements in the field of orthopedics such as the invention of robotic minimally invasive procedures, and the rising healthcare related consumer expenditure are some of the growth drivers for the market. The future sustainability of the market will be ensured by the economic growth in the Asia Pacific and Latin American regions.  Joint replacement and reconstruction market held majority of the market share in 2011...
Bentonite Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Bentonite also called as montmorillonite is a clay which has ability to produce electrical charge upon being hydrated. Bentonite is recognized for its capability to soak up and eradicate toxins, impurities, heavy meats and chemicals. Bentonite is used in variety of foods such as yogurts and candy. Smoothness of yogurt is created by bentonite. Bentonite is also used in manufacture of medicines due to its good water holding capabilities. Bentonite is used as bonding material in metal casting industry. Bentonite can also be mixed with clay and sand to be used in ceramics and...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...